Literature DB >> 1426880

Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria.

R Eissele1, H Patberg, H Koop, W Krack, W Lorenz, A T McKnight, R Arnold.   

Abstract

Hyperplasia of the oxyntic enterochromaffinlike cells in response to long-lasting blockade of acid secretion is closely related to hypergastrinemia. In the present study, the effect of a specific gastrin receptor antagonist on proton pump inhibitor-induced changes on serum gastrin levels, mucosal height, as well as gastrin- and enterochromaffin-like cells was investigated in rats. The proton pump inhibitor BY 308 or the vehicle methylcellulose [Methocel (controls)] was administered for 2 weeks in the presence and absence of the gastrin receptor antagonist PD 136450 (CAM 1189). BY 308 significantly increased serum gastrin levels, gastrin cell density, and antral gastrin concentration. Concomitant application of PD 136450 did not alter this response. In the oxyntic stomach, mucosal height, enterochromaffinlike cell density, labeling index of enterochromaffinlike cells, and histamine concentration were elevated after treatment with BY 308. These increases were almost completely abolished by PD 136450. Even in normogastrinemic control rats, PD 136450 significantly decreased mucosal height of the oxyntic part of the stomach and the labeling index of enterochromaffinlike cells. The results show that (a) trophic effects of drug-induced achlorhydria are mediated by gastrin; (b) even in control rats (normogastrinemic), gastrin is a trophic factor for the oxyntic mucosa; and (c) antral gastrin cell hyperplasia in states of chronic achlorhydria is not mediated by gastrin itself.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1426880     DOI: 10.1016/0016-5085(92)91183-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Gastrin, somatostatin, and experimental disturbance of the gastrointestinal tract in rats.

Authors:  Y L Yao; B Xu; W D Zhang; Y G Song
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Attenuation of stress-induced gastric lesions by lansoprazole, PD-136450 and ranitidine in rats.

Authors:  S I Chandranath; S M A Bastaki; A D'Souza; A Adem; J Singh
Journal:  Mol Cell Biochem       Date:  2010-11-30       Impact factor: 3.396

3.  Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide.

Authors:  T D'Adda; B Annibale; G Delle Fave; C Bordi
Journal:  Gut       Date:  1996-05       Impact factor: 23.059

4.  Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.

Authors:  A el-Nujumi; C Williams; J E Ardill; K Oien; K E McColl
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

5.  Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas.

Authors:  Melanie L Richards; Paul Gauger; Norman W Thompson; Thomas J Giordano
Journal:  World J Surg       Date:  2004-06-16       Impact factor: 3.352

6.  Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat.

Authors:  A Schmassmann; A Garner; B Flogerzi; M Y Hasan; M Sanner; L Varga; F Halter
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

7.  PD-136,450: a CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity.

Authors:  S M A Bastaki; M Y Hasan; S I Chandranath; A Schmassmann; A Garner
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

8.  Histamine as an intermediate growth factor in genesis of gastric ECLomas associated with hypergastrinemia in mastomys.

Authors:  I M Modlin; R R Kumar; C J Soroka; H Ahlman; O Nilsson; J R Goldenring
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

Review 9.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

10.  A new CCK-B/gastrin receptor antagonist acts as an agonist on the rat pancreas.

Authors:  I Koop; R Eissele; S Richter; H Patberg; F Meyer; J Mössner; R Arnold; H Koop
Journal:  Int J Pancreatol       Date:  1994-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.